Correction

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel (vol 28, pg 2768, 2017)

ANNALS OF ONCOLOGY (2022)

Volume 33, Issue 3, Pages 355-355

DOI: 10.1016/j.annonc.2021.12.008

Click your name to claim this paper and add it to your profile.